NEW YORK (GenomeWeb News) – Presenting at an investors meeting in London this week, Roche said this week that is has more than 200 companion diagnostic projects ongoing across its pharma and diagnostics units. "More than 60 percent of our pharmaceutical pipeline projects are couples with the development of companion diagnostics in order to make treatments more effective," Roche CEO Severin Schwan said.

The firm also noted that approximately 50 percent of its R&D budget is allocated to oncology drugs and diagnostics.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.